Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,558.40
(
0.01%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
101.99
(
0.45%
)
Bitcoin
77,789.40
(
-1.10%
)
News Focus
News Focus

Replies to post #548324 on NorthWest Biotherapeutics Inc (NWBO)

Replies to #548324 on NorthWest Biotherapeutics Inc (NWBO)
icon url

HyGro

12/13/22 1:44 PM

#548332 RE: SkyLimit2022 #548324

The validity of the trial data is critical to the Risk/Benefit. If the data is questionable after their review of the trial deficiencies that the Risk/Benefit is clear. Been the same for many biotechs that failed their regulatory review.